• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Jan Berger, MD, MJ, Addresses Challenges in Oncology Management

Article

"Oncology is a very emotional area," says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits.

"Oncology is a very emotional area," says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits. "It is emotional for the payers and it's emotional for the providers because they really fight and struggle to keep their patients not only alive, but to have a great quality of life."

Dr Berger also says payers and providers must be brought together in order to benefit the patient and deliver personalized care.

Related Videos
Ivo Carre, PhD, senior business analyst, Lifescience Dynamics
Antonio Urbina, MD
Drs Yelena Janjigian and Zev Wainberg | Background image credit: ipopba - stock.adobe.com
Tina Bhatnagar, DO
Peter Voorhees, MD, Atrium Health Levine Cancer Institute
Antonio Urbina, MD
Ciara Zachary, PhD, MPH
Hearn Jay Cho, MD, PhD
Nicoletta Colombo, MD, PhD
Related Content
Prerna Mewawalla, MD

Redesigning Trials for Real-World Patient Complexity: A Q&A With Prerna Mewawalla, MD

December 4th 2025
Article

Prerna Mewawalla, MD, discusses innovative strategies to enhance cancer care access, reduce clinician burden, and improve clinical trial diversity in real-world settings.

Read More

Managed Care Cast

Frameworks for Advancing Health Equity: Dental Health Care Access

December 2nd 2025
Podcast

Explore innovative strategies in dental care that are enhancing access, promoting health equity, and improving community health in Pennsylvania.

Listen

FDA approval | Image Credit: Olivier Le Moal - stock.adobe.com

FDA Approves Durvalumab With FLOT Chemotherapy for Resectable Gastric and Gastroesophageal Junction Cancer

November 25th 2025
Article

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

Read More

Managed Care Cast Square thumbnail

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025
Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

FDA approval. | Image credit: aznan – stock.adobe.com

FDA Approves Gene Therapy Onasemnogene Abeparvovec for Broader SMA Population

November 25th 2025
Article

Onasemnogene abeparvovec-brve is now the first gene replacement therapy approved for spinal muscular atrophy in patients 2 years and older.

Read More

AJMC Q&A with Svetlana Barbarash | Background image credit: ipopba – stock.adobe.com

Women’s Subtle Arrhythmia Symptoms Are Often Overlooked: Svetlana Barbarash, MD

November 24th 2025
Article

Svetlana Barbarash, MD, explains how better education, digital monitoring tools, and coordinated care can improve arrhythmia detection and outcomes.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.